CVS Health said on November 4, 2026 it will split in two by the first half of 2028, keeping Caremark with Aetna and spinning off its 9,000 pharmacies.
Last updated: November 6, 2026
On November 4, 2026, CVS Health announced it will separate into two publicly traded companies by the first half of 2028. Aetna, CVS Caremark and CVS Specialty stay together under CVS Health. About 9,000 retail pharmacies, mail pharmacy, MinuteClinic and Health100 become CVS Pharmacy.
This page covers what CVS announced, why it is splitting now, which CVS business a drugmaker will be dealing with after the separation, and the milestones to track through 2028.
What did CVS Health announce on November 4, 2026?
CVS Health said it intends to separate into two independent, publicly traded companies after a strategic review by its board. Shareholders will own shares in both. The separation is intended to be tax free for US federal income tax purposes and is expected to be completed in the first half of 2028.
Completion is subject to final board approval, an effective Form 10 registration statement with the SEC, and confirmation of the tax free treatment. Until then, the company says it will keep operating as it does today. David Joyner, chairman and CEO, will run the healthcare solutions company, which keeps the CVS Health name for now. Prem Shah, currently group president, will become CEO of CVS Pharmacy. Other leadership and board seats will be named later. Goldman Sachs is lead financial advisor, Consello is a financial and strategic advisor, and Wachtell, Lipton, Rosen & Katz is legal counsel.
| Business | Goes to CVS Health (healthcare solutions) | Goes to CVS Pharmacy (retail and community health) |
|---|---|---|
| Aetna health insurance (about 37 million people served) | Yes | |
| CVS Caremark PBM (about 87 million plan members) | Yes | |
| CVS Specialty pharmacy | Yes | |
| Oak Street Health and Signify Health | Yes | |
| About 9,000 retail pharmacies | Yes | |
| Mail pharmacy | Yes | |
| MinuteClinic, including virtual care | Yes | |
| Health100 technology services business | Yes (both companies will keep developing it) |
Scale figures are as of September 30, 2026, from the CVS Health release.
Why is CVS breaking up now?
CVS is splitting while its numbers are improving, not during a crisis. The same morning, it reported third quarter revenue of $108.4 billion, up 5.4%, adjusted earnings of $2.09 per share against $1.60 a year earlier, and raised full year guidance for the third time in 2026.
| CVS Health, third quarter | 2026 | 2025 |
|---|---|---|
| Total revenues | $108.4B | $102.9B |
| GAAP diluted EPS | $1.68 | −$3.13 (included a $5.7B goodwill impairment) |
| Adjusted EPS | $2.09 | $1.60 |
| Full year 2026 adjusted EPS guidance | At least $8.20, up from $7.90 to $8.10 | |
| Full year 2026 cash flow from operations guidance | At least $15.5B, up from at least $11.5B | |
Joyner said in the release that the company is acting “from a position of strength,” and on the investor call he said regulatory pressure was not the reason, according to Healthcare Dive. The company argues that two focused businesses with separate capital structures will move faster.
The regulatory backdrop is still hard to ignore. Arkansas passed Act 624 in April 2025 to bar PBMs from owning pharmacies in the state. A federal judge blocked it with a preliminary injunction in July 2025, and the state board of pharmacy filed a notice of appeal. Healthcare Dive reports that CVS is also challenging a similar Tennessee law and that a bipartisan group in Congress has introduced comparable federal legislation. Leerink analyst Michael Cherny said the split could help CVS sidestep continuing state scrutiny of vertical integration, while J.P. Morgan’s Lisa Gill said she sees some logic to it.
Our read: whatever the motive, the structure CVS chose separates the piece lawmakers have targeted most directly, PBM ownership of retail pharmacies, while keeping the insurer, the PBM and the specialty pharmacy under one roof.
Which CVS company will drugmakers deal with after the split?
For most manufacturer relationships, the counterparty does not change. Formulary and rebate contracting sits with Caremark, and specialty dispensing sits with CVS Specialty, and both stay inside CVS Health with Aetna. The relationships that move are retail dispensing, mail pharmacy, MinuteClinic and pharmacist services, which go to CVS Pharmacy.
| Manufacturer touchpoint | Counterparty after separation | What to watch |
|---|---|---|
| Commercial formulary, rebates, utilization management | CVS Caremark (CVS Health) | Whether Caremark changes its network economics once it no longer owns the largest retail chain |
| Specialty pharmacy and limited distribution networks | CVS Specialty (CVS Health) | Little structural change; critics’ concerns about PBM affiliated specialty dispensing remain |
| Retail dispensing and trade relations | CVS Pharmacy | New, separate contracting and data agreements with an independent chain |
| Mail pharmacy | CVS Pharmacy | How mail fulfillment for Caremark members will be contracted between the two companies; not described in the release |
| Vaccines, MinuteClinic, pharmacist delivered services | CVS Pharmacy | CVS Pharmacy says it will pursue partnerships with payers, PBMs and manufacturers |
| Aetna medical benefit and value based care programs | CVS Health | Unchanged pairing with Oak Street Health and Signify Health |
The mail pharmacy line is the one most likely to surprise readers. Mail order is a standard PBM channel for maintenance prescriptions, yet CVS’s mail operation travels with the retail company rather than with Caremark. CVS’s third quarter 10-Q already describes the retail segment as providing fulfillment support for the PBM’s specialty and mail offerings, so some form of intercompany agreement looks likely. The terms have not been disclosed.
Does the CVS split change drug prices or PBM rebates?
Not directly, according to the company. A CVS spokesperson told Healthcare Brew the split will have no effect on drug prices. Rebate negotiations stay with Caremark, which keeps its scale of about 87 million plan members and its pairing with Aetna and CVS Specialty.
Critics argue that is exactly the point. Adam Fein, a drug channel consultant, told the Advisory Board that by keeping specialty with its PBM and insurance arms, CVS still owns a dispensing business and still profits from drug spend. For manufacturers of high cost specialty products, that means the integrated insurer, PBM and specialty pharmacy model they negotiate against today survives the breakup intact.
The change that could matter more over time is on the retail side. An independent CVS Pharmacy has its own incentive to win business from every PBM, including Express Scripts and Optum Rx, rather than serving as the retail arm of one. CNBC reports that Leerink’s Cherny pointed to CostVantage, CVS’s newer pharmacy reimbursement model, as a reason pharmacy margins have stabilized. Watch whether CVS Pharmacy pushes that model harder with outside PBMs once it stands alone.
How does the CVS breakup compare with other 2026 healthcare separations?
CVS joins a busy year for healthcare breakups, and it has the longest runway of the group. It is targeting the first half of 2028, roughly 14 to 20 months after the announcement, against Abbott’s end of 2027 target for a business announced two weeks earlier.
| Separation | Announced or completed | Structure | Status |
|---|---|---|---|
| CVS Health: CVS Pharmacy separation | Announced November 4, 2026 | Intended tax free separation; shareholders own both | Expected first half of 2028 |
| Abbott: nutrition business (about $8.5B annual sales) | Announced October 21, 2026 | Tax free distribution of shares | Expected by end of 2027 |
| Medtronic: MiniMed diabetes business | Completed October 15, 2026 | Exchange offer | Complete; Medtronic holds no stake |
| BD: Biosciences and Diagnostic Solutions to Waters | Completed February 9, 2026 | Spin and combination with Waters | Complete |
The common thread is focus. Each parent company is betting that investors will pay more for simpler businesses with one growth story. CVS’s case is unusual because its parts are tied together by customers: Caremark members fill prescriptions at CVS stores and through CVS mail, and those flows now have to be governed by contracts rather than ownership.
What should pharma market access and trade teams do now?
Nothing changes operationally today, and CVS says it will run as one company until the separation closes. A runway of more than a year is still useful planning time. Here is a practical checklist, based on the structure CVS has disclosed so far.
- Map every CVS contract to its future owner. Separate Caremark rebate and formulary agreements, CVS Specialty network agreements, retail trade and data agreements, mail pharmacy terms and MinuteClinic or vaccine programs. Flag any agreement signed at the CVS Health parent level that covers both sides.
- Check assignment and change of control clauses. Contracts that name CVS Health as the counterparty may need to be assigned or split in 2028. Legal teams should know which clauses apply before the Form 10 is filed.
- Watch the intercompany agreements. The Form 10 and related filings should describe how Caremark will buy retail and mail dispensing from CVS Pharmacy. Those terms will tell you whether CVS stores keep preferred status in Caremark networks.
- Revisit data rights. Dispensing data from retail and mail will sit with CVS Pharmacy, while claims and utilization data sit with Caremark and Aetna. Patient support, adherence and hub programs that rely on both data sets may need two agreements.
- Plan for a more open retail partner. CVS Pharmacy says it wants partnerships with manufacturers, payers and PBMs. Brand teams with adherence, vaccination or pharmacist counseling programs may find a more willing counterpart than before.
- Track PBM policy in 2027. State ownership laws, the Arkansas appeal and federal PBM bills could all move before the split closes, and any one of them could change the final structure.
What should you watch next?
| Milestone | Timing | Why it matters |
|---|---|---|
| Additional leadership and board appointments | “At a later date,” per CVS | Signals how each company will be run and who owns manufacturer relationships |
| Form 10 registration statement filed with the SEC | Not yet dated | First detailed look at intercompany agreements, financials and risk factors for CVS Pharmacy |
| Arkansas Act 624 appeal | Pending | A ruling upholding the law would strengthen the case for state PBM ownership bans |
| State and federal PBM legislation | 2027 sessions | Healthcare Dive expects continued scrutiny after the midterm results |
| Separation completed | First half of 2028 | CVS Pharmacy begins trading as an independent company |
Frequently asked questions
Is CVS Health splitting up?
Yes. On November 4, 2026, CVS Health announced plans to separate into two publicly traded companies, a healthcare solutions company that keeps the CVS Health name for now and a retail pharmacy company called CVS Pharmacy. Completion is expected in the first half of 2028.
Will Caremark stay with Aetna?
Yes. CVS Caremark, the pharmacy benefit manager, stays with Aetna, CVS Specialty, Oak Street Health and Signify Health in the healthcare solutions company led by David Joyner.
What will CVS Pharmacy include?
About 9,000 retail pharmacies, the mail pharmacy, MinuteClinic including virtual care, and the Health100 technology services business. Prem Shah, currently CVS Health group president, will be CEO.
When will the CVS split be completed?
CVS expects to complete the separation in the first half of 2028, subject to final board approval, an effective Form 10 registration statement and confirmation of tax free treatment.
Will the CVS split lower drug prices?
The company says no. A CVS spokesperson told Healthcare Brew the split will have no effect on drug prices. Rebate negotiations remain with Caremark, which keeps its scale and its pairing with Aetna.
Who will pharmaceutical companies negotiate rebates with after the split?
Caremark, inside the healthcare solutions company. Retail dispensing, mail pharmacy and MinuteClinic relationships move to CVS Pharmacy, which says it will pursue partnerships with manufacturers, payers and PBMs.
Where does CVS Specialty pharmacy go?
CVS Specialty stays with Caremark and Aetna in the healthcare solutions company. Critics, including consultant Adam Fein, argue that keeping specialty with the PBM preserves the integrated model regulators have questioned.
Why did CVS decide to split?
CVS says two focused companies will be more agile, with separate capital structures and strategies. CEO David Joyner said the move comes from a position of strength and that regulatory pressure was not the reason, according to Healthcare Dive.
How did CVS perform in the third quarter of 2026?
Revenue was $108.4 billion, up 5.4%, with adjusted earnings of $2.09 per share versus $1.60 a year earlier. CVS raised 2026 guidance to at least $8.20 in adjusted earnings per share.
What is Arkansas Act 624?
A 2025 Arkansas law that would bar pharmacy benefit managers from owning pharmacies in the state. A federal judge blocked it with a preliminary injunction in July 2025, and the state appealed.
Sources
- CVS Health press release, “CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare,” November 4, 2026, and SEC Form 8-K dated November 4, 2026 (primary)
- CVS Health third quarter 2026 results release, November 4, 2026, SEC Form 8-K exhibit 99.1 (primary)
- CVS Health Form 10-Q for the quarter ended September 30, 2026 (primary)
- Healthcare Dive, republished by BioPharma Dive, November 4, 2026: investor call account, analyst comments, Tennessee and federal legislation context (attributed)
- CNBC, November 4, 2026: analyst commentary including CostVantage (attributed)
- Healthcare Brew, November 2026: CVS spokesperson statement on drug prices (attributed)
- Advisory Board Daily Briefing, November 5, 2026: Adam Fein comments (attributed)
- Mintz and KARK reporting on the Arkansas Act 624 preliminary injunction and appeal, July and August 2025 (attributed)
- BioMed Nexus coverage of the Abbott, Medtronic MiniMed and BD separations (dates and structures from primary releases cited in those articles)
Related coverage
- How drug pricing actually works, from list price to rebates
- Abbott will spin off its $8.5 billion nutrition business
- Medtronic completed the MiniMed separation
- Biotech in 2027: what to watch
- Browse the BioMed Nexus industry directory
BioMed Nexus tracks PBM, pricing and market access moves every business day. Get the daily briefing free.
